Acetazolamide in X-linked Retinoschisis

INTERVENTION: Oral acetazolamide 200mg twice a day >60kg or 125mg twice <60kg. Participants allocated to the acetazolamide/placebo study arm will receive acetazolamide first, followed by placebo, and vice versa in the placebo/acetazolamide. The duration of acetazolamide will be three months. The mode of administration is oral capsule. Cross over occurs at 3 months following first dose of treatment. Measurements at are done at 0, 3 and 6months. Hence no "wash‐out" period is required. CONDITION: X‐linked Retinoschisis PRIMARY OUTCOME: Best corrected visual acuity using Snellen and Log MAR Chart Macular cyst size using optical coherence tomography (OCT) Retinal thickness using optical coherence tomography (OCT) SECONDARY OUTCOME: Nil INCLUSION CRITERIA: ‐ Patients with X‐linked retinoschisis diagnosis and stable ocular fixation with no clinically significant media opacities. There will be no age restrictions